CELLFINA™ SYSTEM LAUNCHES NATIONWIDE AT THE AMERICAN SOCIETY FOR AESTHETIC PLASTIC SURGERY. Data on New Treatment Also Being Presented At Annual Meeting
Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group) announced today that its Cellfina™ System will launch nationwide at the Annual Meeting for the American Society for Aesthetic Plastic Surgery in Las Vegas, NV. Cellfina is the only FDA-ˇcleared, minimally invasive procedure clinically proven to improve the appearance of cellulite for results that last at least two years – the longest duration cleared by the FDA.
“Merz Aesthetics is proud to bring Cellfina to physicians across the country. We chose the annual meeting of Aesthetic Plastic Surgeons as the venue to make this technology widely available because of the long heritage this meeting has of introducing key advances in aesthetics,” said Patrick Urban, Vice President and Head of the Merz Aesthetics Device Division. “Additionally, the new Cellfina safety and efficacy data we will be presenting at the meeting are further evidence of Merz Aesthetics’ commitment to continued innovation and expansion of the aesthetic space.”
The Cellfina System presentation (Abstract 341), titled “Pivotal Safety and Efficacy Study of a New Precision-ˇGuided Tissue Release Cellulite Treatment” will be presented by Dr. Simeon Wall and will highlight new outcome data from the pivotal prospective, multi-ˇcentered study.
Additionally, Merz Aesthetics will be hosting an educational booth discussion around the Cellfina System at 1 p.m. on Monday, April 4, featuring Drs. Grant Stevens, Laurie Casas, and Tiffany McCormack.
“As one of the very early adopters of Cellfina, it is exciting to see technology added to our tool chest. This transformative device will impact and expand the aesthetic market and provides an accurate and successful treatment option for our patients that is minimally invasive and can be performed under local anesthesia,” said Dr. Brad Bengtson, a board-ˇ certified plastic surgeon from Grand Rapids, MI. “The immediate results and significant improvement in the outcomes is proof enough for me that we finally have something that actually works for dimpled cellulite.”
The Cellfina System is intended for long-ˇterm improvement in the appearance of cellulite in the buttocks and thigh areas of adult females.
Safety and effectiveness in other anatomical areas have not been established. The most common side effects reported were soreness, tenderness, and bruising. The Cellfina System is only available through a licensed physician. For full product and safety information, visit cellfina.com/IFU.
About Merz Aesthetics
Merz Aesthetics is a division of Merz North America, a specialty healthcare company that develops and commercializes treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. As part of the Merz Pharma Group of companies, our ambition is to become the most admired, trusted and innovative aesthetics and neurotoxin company. By developing products that improve patients’ health and help them to live better, feel better and look better, Merz will continue to make significant contributions to the well-ˇbeing of individuals around the world. Merz Aesthetics provides a range of treatment options, including devices, injectables and skincare, that enable physicians to use Merz technologies to treat a variety of patients and concerns. For more information about Merz Aesthetics and their U.S. product portfolio, please visit www.merzusa.com.
With approximately 3,000 employees and 34 subsidiaries worldwide, Merz is a global leader in Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. Complementing its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy for the treatment of movement disorders. Skincare products and a range of OTC medicines are also included in offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2016/17, the Merz Pharma Group generated revenue of EUR 1,023.2 million. More information is available at www.merz.com.
04.01.2016 [ 0 KB ]
Merz North America